Meeting
2014 ASCO Annual Meeting
ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse.
Authors
Simon Abi Aad
MD Anderson Cancer Center, Houston, TX
Simon Abi Aad , Naval Guastad Daver , Paolo Strati , Jorge E. Cortes , Guillermo Garcia-Manero , Michael Mathisen , Farhad Ravandi , Tapan M. Kadia , Susan Mary O'Brien , Carol Bivins , Sherry Pierce , Hagop M. Kantarjian , Elias Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7074)
DOI
10.1200/jco.2014.32.15_suppl.7074
Abstract #
7074
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
First Author: Katherine Tarlock
Poster
2023 ASCO Breakthrough
Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: Implications for hippocampal sparing irradiation.
First Author: Jooho Lee
Poster
2023 ASCO Annual Meeting
Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.
First Author: Uday R. Popat
Poster
2018 ASCO Annual Meeting
Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.
First Author: Prajwal Boddu